中文简体
中文繁体
English
ABOUT IASO
Company Overview
Management Team
Scientific Advisory Board
Partnership
SCIENCE & PRODUCTS
Pipeline
Technology Platforms
Manufacturing
Publictaions
Expanded Access
NEWS
Press Release
Media Report
CAREERS
Working at IASO
Opportunities
CONTACT
NEWS
Press Release
Media Report
Search
21
2025-10
IASO Bio Announces Approval of Clinical Trial Notification for its BCMA CAR-T Product in Japan
16
2025-10
Cell Publishes Breakthrough Research Results of IASO Bio's Anti-BCMA CAR-T Equecabtagene Autoleucel in Autoimmune Disease Multiple Sclerosis
19
2025-09
2025 IMS | IASO Bio Highlights Three-Year Follow-Up Data of CAR-T Cell Therapy Fucaso for Multiple Myeloma Treatment
12
2025-09
IASO Bio to Present Promising Findings on Equecabtagene Autoleucel for Multiple Sclerosis at both ANA and ECTRIMS 2025
09
2025-07
IASO Bio Receives Orphan Drug Designation from the Ministry of Food and Drug Safety of South Korea for Equecabtagene Autoleucel
23
2025-06
IASO Bio presents promising efficacy of Equecabtagene Autoleucel in patients with Multiple Sclerosis in IIT study at the 11th Congress of the European Academy of Neurology (EAN)
20
2025-05
IASO Bio Celebrates Grand Opening of Shanghai Waigaoqiao Global R&D Center and Successfully Hosts Forum on China's Cell Therapy Globalization
09
2025-05
IASO Bio Receives Orphan Drug Designation from the Saudi Food and Drug Authority for Equecabtagene Autoleucel
28
2025-03
IASO Bio Announces Approval of New Drug Application for Equecabtagene Autoleucel by the Macau Pharmaceutical Administration Bureau
14
2025-02
IASO Bio Announces Acceptance of New Drug Application for Equecabtagene Autoleucel (FUCASO) by the Hong Kong Department of Health
<
1
2
3
4
5
>
